The company has also joined the Cancer Moonshot program, working within its Blood Profiling Atlas Project on pre-analytical variation in molecular tests.
The evaluation presented at SABCS last week highlighted the importance of considering node-positive and -negative patients, and incorporating clinical information with molecular tests.
The firm expects that the CE-marked i-STAT Alinity will eventually replace the existing i-STAT instrument, which is in one of every three hospitals.
The firm’s emphasis on automation has yielded Dx products for blood banks, assays for HIV and acute kidney injury, and flexible diagnostic test systems that can adapt to labs’ changing needs.
The stool-based test was approved by US regulators in 2014 and included as an A-rated service in the US Preventive Services Task Force's colorectal cancer screening guidelines earlier this year.
Invitae will test 1,000 breast cancer patients from TME practices using its hereditary cancer test, regardless of whether they meet current eligibility criteria.
Progression-free and overall survival seen in the veliparib arm weren't statistically significant, but were encouraging enough to move the drug to Phase III, AbbVie said.
The new agreement brings Interpace's total insurance coverage for its thyroid assays to approximately 200 million patients.
Notable is adopting Labcyte's Echo acoustic liquid handling platform to screen cancer patients' tumor cells for response to individual and combination therapies.
The Teva Pharmaceuticals subsidiary will have exclusive rights to distribute NantHealth's comprehensive molecular cancer test in Israel.
The company is planning to work with up to 40 sites, with an initial goal of sequencing circulating cell-free DNA from 10,000 people.
The company said it will use the proceeds of the financing to continue the development of a technology platform and associated applications.
Lunatus will have exclusive rights to distribute GPS Cancer to physicians in the UAE, Saudi Arabia, Kuwait, Oman, Bahrain, Qatar, and Lebanon.
The company has rededicated itself to a fully blood-based test pipeline, with its next assays focused on women's health, including endometriosis and ovarian, uterine, and cervical cancers.
ClinGen's cancer somatic working group hopes the adoption of its Minimal Variant Level Data (MVLD) framework will facilitate data exchange between institutions and help with variant interpretation.
One group pointed out differences between study group characteristics, while the other wondered about the role of patient preference.
The certification ensures that the biobank has the authority to handle and test human samples for the Cancer MoonShot 2020 initiative.
The firms have eliminated several terms of their original deal and have cross-licensed IP to allow Med BioGene to license Gene FX Lung to other firms.
The new assay, called the CellMax-DNA Genetic Cancer Risk Test, will complement CellMax Life's planned slate of liquid biopsy assays for early cancer detection.
Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.